Catalysts / APVO
Upcoming FDA decisions and readouts we track for Aptevo Therapeutics, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Aptevo Therapeutics (APVO, listed on Nasdaq). They cover 2 programmes: Mipletamig + venetoclax/azacitidine (Frontline acute myeloid leukaemia) and Mipletamig (Frontline acute myeloid leukaemia).
First on the list: the Phase 1B/2 readout for Mipletamig + venetoclax/azacitidine (Frontline acute myeloid leukaemia), guided by the company to Late 2026. By stage, the upcoming rows are 1 Phase 1B/2 readout and 1 Regulatory milestone.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; Why catalyst windows like "H2 2026" are vague, and how they narrow.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Aptevo Therapeutics APVO · Nasdaq | Mipletamig + venetoclax/azacitidine | Frontline acute myeloid leukaemia | Late 2026 company guidance |
Phase 1B/2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Aptevo Therapeutics APVO · Nasdaq | Mipletamig | Frontline acute myeloid leukaemia | H1 2027 company guidance |
Regulatory milestone | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList